SEQRYPTON, Inc. is a cyber and physical security company powered by AI and quantum cryptography. At CES 2026, SEQRYPTON presents PriviCam, a privacy-safe video surveillance camera that anonymizes personal data at the sensor level, ensuring that no private images can be exposed even if cameras or streaming servers are compromised.
Seoul Bio hub
Seoul Bio Hub, located in northern Seoul and opened in October 2017, is a life science innovation center sponsored by the Seoul Metropolitan Government and operated by Korea Institute of Science and Technology(KIST) and Korea University(KU). The key function is to support early stage life science companies’ growth and commercialization by providing full service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity.
Seoul Biohub
Seoul Bio Hub, located in northern Seoul and opened in October 2017, is a life science innovation center sponsored by the Seoul Metropolitan Government and operated by Korea Institute of Science and Technology(KIST) and Korea University(KU). The key function is to support early stage life science companies’ growth and commercialization by providing full service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity. With a total of 33,105 square feet, the seven buildings include state-of-the-art laboratories, offices, meeting rooms, seminar rooms, amenities, and more. | * Linkedin: https://www.linkedin.com/company/seoulbiohub/posts/?feedView=all * Area: Biotech, Medical Devices, Startups, Drug Development, Digital Health, Life Sciences and Laboratory Services Seoul Bio Hub, located in northern Seoul and opened in October 2017, is a life science innovation center sponsored by the Seoul Metropolitan Government and operated by Korea Institute of Science and Technology(KIST) and Korea University(KU). The key function is to support early stage life science companies’ growth and commercialization by providing full service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity. The 21,937-square meter site houses three buildings with a total floor area of 9,564 square meters consisting of labs, offices, a special lab, a core facility room, an industry-academia collaboration center, conference rooms, seminar rooms, and amenities.
Seoul Labs Inc.
Seoul Labs develops advanced Web3 infrastructure built on its own Layer-1 blockchain technology. We provide secure digital identity, e-signature, and payment solutions that support governments and enterprises in deploying scalable, reliable, and future-ready digital services across global markets.
Seoul National University Hospital (SNUH)
Seoul National University Hospital (SNUH) is South Korea’s leading medical institution, renowned for excellence in patient care, medical research, and education. Established in 1885, SNUH has played a pivotal role in advancing healthcare and medical sciences in the country. SNUH is dedicated to pioneering medical research, contributing to global medical advancements through innovative treatments and clinical trials. The hospital also plays a crucial role in training future medical professionals, fostering excellence in both academic and practical medical education. With a commitment to patient-centered care, SNUH continues to provide high-quality medical services, ensuring the well-being of patients from Korea and around the world. Seoul National University Hospital was designated as the 1st National Strategic Technology Research Institute (NSTRI) from the ministry of Healthcare and Welfare of Korean government. NSTRI is designated to perform crucial functions for the stable and strategic development of advanced bio-technologies. The institute operates with three key focus areas: 1) the development of an “advanced bio-research data platform,” 2) the establishment of a “digital bio international cooperation ecosystem,” 3) the cultivation of “core talent in physician-scientists.” For more information, please visit here 🙂 http://www.snuh.org/english https://nstri-en.snuh.org
Seoul National University R&DB Foundation
Discover the Power of Innovation at the Seoul National University Pavilion | BIO International 2025, Boston Join us in Boston at BIO 2025 and experience the forefront of biomedical innovation through the Seoul National University (SNU) Pavilion, where academic excellence meets translational impact. At the SNU R&DB Foundation, we champion world-class research by managing intellectual property, accelerating technology transfer, and advancing commercialization. We foster interdisciplinary collaboration, empower academia-industry partnerships, and nurture entrepreneurial growth among SNU’s researchers and students. At Booth #2879, we are proud of presenting a curated selection of next-generation technologies available for global licensing and collaboration, including: • First-in-class small molecules and antibodies targeting liver cancer and MASH • Novel peptides with superior hair growth efficacy • Broad-spectrum antibiotics with powerful efficacy against multidrug-resistant superbugs, developed through drug repositioning • Short peptides with a new mode of action offering both anti-inflammatory and anti-cancer effects, including IBD • Next-generation mesothelin-targeting antibody engineered to overcome proteolytic degradation; and • More game-changing innovations shaping the next era of biotechnology. Explore the future of Korean biotech through seven innovative SNU spin-off companies, each pushing the boundaries of science and commercialization: AIGENDRUG | AI-driven drug discovery platform(DrugVLAB) | www.aigendrug.com CellBion | Radiopharmaceuticals & radioligand therapy | www.cellbion.co.kr CELLinCELLS | Organoid tissue module manufacturing technology | www.cellincells.com ClichemBIO, Inc. | Albumin-based nano theranostics platform for precision nano-medicine | www.clichembio.com Molecular Innovations Inc. | Multifunctional small molecules (Resveratron) for improving skin health and metabolic diseases NIBEC | Proprietary peptides, regenerative biomaterials, and drug delivery systems | https://nibec.co.kr/en/ Portrai | Spatial Transcriptomics-based Drug Discovery Solutions and AI Pathology Analysis System | www.portrai.io We cordially invite you to visit the SNU Pavilion and explore powerful opportunities for partnership, co-development, and strategic investment. Let’s build the future of biotech—together. Meet us in Boston, and let innovation begin. | Seoul National University (SNU) Pavilion | BIO International Convention 2026 Discover Partner-Ready Innovation from One of Asia’s Leading Research Universities Join the Seoul National University (SNU) Pavilion at BIO 2026 and connect with a premier hub of translational research and global partnering. Backed by a strong track record in intellectual property management, technology transfer, and successful commercialization, the SNU R&DB Foundation serves as the gateway to high-impact biomedical innovations from Korea’s top-ranked university. We actively collaborate with global pharmaceutical and biotech partners to advance early-stage assets toward clinical and commercial success. Our portfolio is built on rigorous science, validated targets, and strong IP positions—designed for efficient licensing and co-development. We will be showcasing selected innovations at Booth #5535 ○ Hepatitis B virus-derived polypeptides and their therapeutic applications ○ An antibacterial or antifungal composition for preventing or treating bacterial or fungal infections (featuring VLX600) ○ Anti-AXL (and Anti-MERTK) antibody and composition containing the same ○ Novel isoxazole compounds as TM4SF5-specific inhibitors and their therapeutic applications ○ Fc Variants for Modulating FcRn Function ○ Novel CD89(Fc α receptor) binding antibodies and their therapeutic applications Explore a curated lineup of innovative SNU spin-off companies, each advancing breakthrough science toward real-world impact and global commercialization. ○ AIGENDRUG | AI Drug Discovery Platform(DrugVLAB) ○ CellBion | Radioligand therapeutics and diagnostics for prostate cancer ○ CELLinCELLS | 3D Tissue Reforming Technology Platform technology, TRTP-101, TRTP-20X ○ ClichemBIO, Inc. | Albumin nanoplatform, New Drug Development ○ NIBEC | Medical Device, Pepetide CDMO, Peptide-based therapeutics ○ SJChem Meditech, Inc | Oral Drug for Atopic Dermatitis ○ Qureator, Inc. | Curiochips®, Human Disease Models, QuriCore AI™ Platform Meet our team to explore partnership opportunities aligned with your pipeline strategy. Pre-arranged meetings are highly encouraged for in-depth discussions and confidential data sharing.
Seoul Viosys Co., Ltd
Seoul Viosys, a subsidiary of Seoul Semiconductor, is a global leader in optical semiconductor technology, pioneering advancements across UV, visible, and next-generation display solutions. The company is at the forefront of MicroLED development, delivering cutting-edge solutions that enable ultra-high resolution, superior color performance, and energy efficiency for next-generation displays in televisions, mobile devices, AR/VR, and automotive applications. Leveraging decades of R&D and a robust portfolio of patented technologies, Seoul Viosys is driving the commercialization of MicroLED technology — offering exceptional brightness and unmatched longevity. As innovators in the global LED market, the company is committed to shaping the future of displays and light-based solutions, creating products that enhance human experiences, sustainability, and technological progress.